Sakai Y, Sasaki T, Imai K, Ibuka T, Koike M, Iwamoto S
Gan To Kagaku Ryoho. 1987 Aug;14(8):2431-43.
Subrenal Capsule Assay (SRCA) developed by Bogden et al. is a new in vivo sensitivity test for anticancer agents. However, the presence of host reaction on about day 6 is largest problem for this method, and now many researchers are scrutinizing or introducing several modifications for this assay chiefly by immunosuppressing procedures. As one of the means to measure the actual change of the tumor volume and minimize the misreading of host reactions, we introduced three dimensional measurements of the grafts (volume method) instead of original mean diameter measurement. Using this method, prospective quantitative study was made. The results of 16 assays with 15 cases of miscellaneous malignancies showed 94% evaluability and in 22 treatments predictive accuracy was 77%. Assay/clinical correlation coefficient was 0.38 and coincidence of ranking order of the effectiveness was 6/6, with good contrast to those of 78%, 56%, 0.00 and 1/3, by original method respectively. Clinical responses more than PR were obtained in 9 of 15 cases. Two cases are still in CR for two years by assay directed single agent treatments. Many other minor modifications were also adopted and evaluated by quantitative observation of assay/clinical correlations. SRCA with our modifications seemed to have utilities than original.
由博登等人开发的肾包膜下测定法（SRCA）是一种用于抗癌药物的新型体内敏感性测试。然而，大约在第6天出现的宿主反应是该方法最大的问题，现在许多研究人员主要通过免疫抑制程序对该测定法进行仔细研究或引入了几种改进方法。作为测量肿瘤体积实际变化并尽量减少对宿主反应误判的方法之一，我们引入了移植物的三维测量（体积法），而不是原来的平均直径测量。使用这种方法进行了前瞻性定量研究。对15例各种恶性肿瘤进行的16次测定结果显示，可评估率为94%，在22次治疗中预测准确率为77%。测定/临床相关系数为0.38，有效性排名顺序的符合率为6/6，与原方法分别为78%、56%、0.00和1/3形成了良好对比。15例中有9例获得了超过PR的临床反应。通过测定指导的单药治疗，有2例患者已持续两年处于CR状态。还采用了许多其他小的改进措施，并通过测定/临床相关性的定量观察进行了评估。经过我们改进的SRCA似乎比原来更有用。
